![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
AE Cribb, M Miller, JS Leeder, J Hill and SP Spielberg
Department of Paediatrics, University of Toronto, Canada.
N4-oxidation of sulfonamides has been implicated in the pathogenesis of idiosyncratic reactions to these antimicrobials. In vitro toxicity assays employing mononuclear leukocytes as target cells have shown that the toxicity of sulfamethoxazole hydroxylamine (SMX-HA) is inhibited by exogenous glutathione, suggesting that conjugation with glutathione is an important detoxification pathway. However, in these experiments, significant depletion of cellular glutathione only occurred at concentrations of SMX-HA greater than or equal to 300 microM. At concentrations of SMX-HA which produce 50% toxicity in mononuclear leukocytes (approximately 100 microM), there was not a significant loss of glutathione. SMX-HA also caused a small but significant increase in oxidized glutathione concentrations. In cell-free experiments, reduced glutathione (GSH) prevented the autooxidation of SMX-HA to nitrososulfamethoxazole (nitroso-SMX). During this process, oxidized glutathione was formed. GSH rapidly reacted with nitroso-SMX to form a labile semimercaptal conjugate. Physiologically relevant concentrations of GSH (i.e. 1 mM) favored thiolytic cleavage of the semimercaptal to form SMX-HA. Isomerization of the semimercaptal to the more stable sulfinamide occurred at low GSH concentrations. Purified glutathione transferases had no effect on the reaction of SMX-HA with GSH. Therefore, glutathione is important in protecting cells from the toxicity of SMX-HA largely by preventing its further oxidation to nitroso-SMX. Stable glutathione conjugates are likely to be formed only in small quantities under physiological conditions. Conjugation with glutathione would not be expected to be a major pathway for clearance of the hydroxylamine and nitroso metabolites of sulfonamides.
This article has been cited by other articles:
|
|
 |
|
  J. P. Sanderson, F. J. Hollis, J. L. Maggs, S. E. Clarke, D. J. Naisbitt, and B. K. Park Nonenzymatic Formation of a Novel Hydroxylated Sulfamethoxazole Derivative in Human Liver Microsomes: Implications for Bioanalysis of Sulfamethoxazole Metabolites Drug Metab. Dispos., December 1, 2008; 36(12): 2424 - 2428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cheng, B. J. Stewart, Q. You, D. R. Petersen, J. A. Ware, J. R. Piccotti, T. T. Kawabata, and C. Ju Covalent Binding of the Nitroso Metabolite of Sulfamethoxazole Is Important in Induction of Drug-Specific T-Cell Responses in Vivo Mol. Pharmacol., June 1, 2008; 73(6): 1769 - 1775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Sanderson, D. J. Naisbitt, J. Farrell, C. A. Ashby, M. J. Tucker, M. J. Rieder, M. Pirmohamed, S. E. Clarke, and B. K. Park Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling J. Immunol., May 1, 2007; 178(9): 5533 - 5542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lin, M J. Tucker, and M. J Rieder Increased Adverse Drug Reactions to Antimicrobials and Anticonvulsants in Patients with HIV Infection Ann. Pharmacother., September 1, 2006; 40(9): 1594 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Feola and B. A. Garvy Combination Exposure to Zidovudine plus Sulfamethoxazole-Trimethoprim Diminishes B-Lymphocyte Immune Responses to Pneumocystis murina Infection in Healthy Mice Clin. Vaccine Immunol., February 1, 2006; 13(2): 193 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Roychowdhury, P. M. Vyas, T. P. Reilly, A. A. Gaspari, and C. K. Svensson Characterization of the Formation and Localization of Sulfamethoxazole and Dapsone-Associated Drug-Protein Adducts in Human Epidermal Keratinocytes J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 43 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Farrell, D. J. Naisbitt, N. S. Drummond, J. P. H. Depta, F. J. Vilar, M. Pirmohamed, and B. K. Park Characterization of Sulfamethoxazole and Sulfamethoxazole Metabolite-Specific T-Cell Responses in Animals and Humans J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 229 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Manchanda, D. Hess, L. Dale, S. G. Ferguson, and M. J. Rieder Haptenation of Sulfonamide Reactive Metabolites to Cellular Proteins Mol. Pharmacol., November 1, 2002; 62(5): 1011 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Naisbitt, J. Farrell, S. F. Gordon, J. L. Maggs, C. Burkhart, W. J. Pichler, M. Pirmohamed, and B. K. Park Covalent Binding of the Nitroso Metabolite of Sulfamethoxazole Leads to Toxicity and Major Histocompatibility Complex-Restricted Antigen Presentation Mol. Pharmacol., September 1, 2002; 62(3): 628 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Svensson, E. W. Cowen, and A. A. Gaspari Cutaneous Drug Reactions Pharmacol. Rev., September 1, 2001; 53(3): 357 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. R. Freund, L. Dousman, J. T. MacGregor, and N. Mohagheghpour Oral Treatment with Trimethoprim-Sulfamethoxazole and Zidovudine Suppresses Murine Accessory Cell-Dependent Immune Responses Toxicol. Sci., June 1, 2000; 55(2): 335 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Reilly, P. M. Woster, and C. K. Svensson Methemoglobin Formation by Hydroxylamine Metabolites of Sulfamethoxazole and Dapsone: Implications for Differences in Adverse Drug Reactions J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 951 - 959. [Abstract] [Full Text]
|
|
|
|
|
|
H. J. Gill, S. J. Hough, D. J. Naisbitt, J. L. Maggs, N. R. Kitteringham, M. Pirmohamed, and B. K. Park The Relationship Between the Disposition and Immunogenicity of Sulfamethoxazole in the Rat J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 795 - 801. [Abstract] [Full Text]
|
|
|
|
|
|
A. E. Cribb, L. R. Pohl, S. P. Spielberg, and J. S. Leeder Patients with Delayed-Onset Sulfonamide Hypersensitivity Reactions Have Antibodies Recognizing Endoplasmic Reticulum Luminal Proteins J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 1064 - 1072. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
